Certified Principal Investigator (CPI®) — Questions and Answers

Question 1: Why is it important to maintain accurate research records?

To meet publication requirements
To ensure data accuracy and transparency (Correct answer)
To reduce costs
To monitor progress

Correct answer: To ensure data accuracy and transparency

Maintaining accurate and complete research records is essential for the credibility and reproducibility of clinical research. Meticulous record-keeping ensures that all data can be verified, supports the transparency of the research process, and allows for proper auditing and regulatory oversight.

Question 2: Under 45 CFR Part 46, research that qualifies for exemption under Category 1 involves which type of participants?

Normal educational practices in established educational settings (Correct answer)
Prisoners and incarcerated individuals only
Pregnant women in third-trimester studies
Cognitively impaired adults in residential facilities

Correct answer: Normal educational practices in established educational settings

Category 1 exemption applies to research involving normal educational practices in established educational settings.

Question 3: What is the primary role of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To audit the sponsor's financial reporting for the trial
To submit IND safety reports to the FDA on behalf of the investigator
To enroll subjects and collect case report forms
To independently review accumulating safety data and recommend trial continuation, modification, or stopping (Correct answer)

Correct answer: To independently review accumulating safety data and recommend trial continuation, modification, or stopping

A DSMB is an independent committee that periodically reviews unblinded safety and efficacy data to protect subjects and ensure ongoing trial integrity.

Question 4: After an emergency unblinding event, which action must the investigator take regarding the IRB?

Notify the IRB only if the event was fatal
No notification is required if the participant recovered fully
Notify the IRB and sponsor of the unblinding event and its circumstances (Correct answer)
Notify the IRB only at the next scheduled continuing review

Correct answer: Notify the IRB and sponsor of the unblinding event and its circumstances

Investigators must promptly report emergency unblinding events to both the IRB and sponsor, documenting the reason and outcome.

Question 5: In the context of clinical trial records, a 'certified copy' is defined as:

A notarized copy stored at the IRB office
A copy signed by the site's legal counsel
A copy that has been verified to be a complete and accurate reproduction of the original document (Correct answer)
Any photocopy of an original document

Correct answer: A copy that has been verified to be a complete and accurate reproduction of the original document

ICH E6(R2) defines a certified copy as one verified to be an accurate and complete reproduction of the original, regardless of medium.

Question 6: When a CRF field is left blank and no data were collected, what is the most appropriate action for the investigator?

Enter 'N/A' without documentation
Leave it blank and move on
Document the reason for missing data according to protocol and sponsor instructions (Correct answer)
Estimate the value based on previous visits

Correct answer: Document the reason for missing data according to protocol and sponsor instructions

Missing data must be documented with the reason according to protocol requirements; fabricating or estimating values without a pre-specified method is a GCP violation.

Question 7: A clinical site's emergency contact list for participants should include all of the following EXCEPT:

Local emergency services (911)
Sponsor's medical monitor emergency line
Participant's personal financial advisor (Correct answer)
24-hour investigator or on-call physician contact

Correct answer: Participant's personal financial advisor

Emergency contact materials for participants include medical contacts (investigator, sponsor medical monitor, emergency services) but not personal financial advisors.

Question 8: Which of the following best describes an 'interim analysis' in a clinical trial?

A sensitivity analysis performed to check assumptions
A post-hoc subgroup analysis requested by regulators
Analysis performed after all data are collected and the database is locked
A pre-specified analysis of accumulating data before trial completion (Correct answer)

Correct answer: A pre-specified analysis of accumulating data before trial completion

An interim analysis is a pre-specified examination of accumulating data during a trial, often used for safety monitoring or adaptive design decisions.

Question 9: What is document version control in CPI?

Same names for all files
Tracking changes, identifying current versions, and maintaining history (Correct answer)
No change tracking
Printing every draft

Correct answer: Tracking changes, identifying current versions, and maintaining history

Version control tracks revisions, identifies current versions, and maintains change history to ensure document integrity.

Question 10: Which regulatory pathway allows emergency use of an unapproved drug outside of a clinical trial when no alternatives exist?

Emergency IND waiver under 21 CFR 312.44
FDA Emergency Use Authorization under 21 CFR 601
Institutional emergency authorization under IRB guidelines
Expanded access (compassionate use) under 21 CFR 312.310 (Correct answer)

Correct answer: Expanded access (compassionate use) under 21 CFR 312.310

21 CFR 312.310 governs individual patient expanded access (compassionate use) for emergency situations where no alternatives are available.

Question 11: In a pragmatic clinical trial, the study conditions are designed to:

Minimize variability by excluding co-morbid patients
Test pharmacokinetics under controlled laboratory conditions
Reflect real-world clinical practice and diverse patient populations (Correct answer)
Maximize internal validity by using strict eligibility criteria

Correct answer: Reflect real-world clinical practice and diverse patient populations

Pragmatic trials prioritize external validity by enrolling broad populations and allowing routine clinical flexibility, contrasting with explanatory (efficacy) trials.

Question 12: The Tuskegee Syphilis Study's primary ethical failure was:

Publishing results without IRB approval
Deliberately withholding effective treatment from infected participants without their knowledge (Correct answer)
Using an unapproved experimental drug without FDA clearance
Enrolling too many participants across too many study sites

Correct answer: Deliberately withholding effective treatment from infected participants without their knowledge

After penicillin became the standard of care, investigators continued withholding treatment to observe disease progression, violating beneficence and respect for persons.

Question 13: During an FDA inspection, an investigator is asked to produce documentation that IP was stored under appropriate conditions throughout the trial. Which record is most directly responsive to this request?

The signed informed consent forms
The IRB correspondence file
The subject screening and enrollment log
The continuous temperature monitoring logs for the IP storage area (Correct answer)

Correct answer: The continuous temperature monitoring logs for the IP storage area

Continuous temperature monitoring logs provide a verifiable record that IP storage conditions remained within protocol-specified ranges for the duration of the study.

Question 14: Which statistical method is most appropriate for analyzing time-to-event data in a clinical trial comparing two treatment arms?

Linear regression
Pearson correlation coefficient
Kaplan-Meier survival analysis with log-rank test (Correct answer)
Chi-square test

Correct answer: Kaplan-Meier survival analysis with log-rank test

Kaplan-Meier survival analysis with the log-rank test is the standard approach for comparing time-to-event outcomes between treatment groups.

Question 15: A protocol mandates that study drug be administered within 30 minutes of a meal. A subject consistently takes the drug 60 minutes after eating. This represents a:

Protocol deviation that must be documented and reported per study procedures (Correct answer)
Protocol violation requiring immediate subject discontinuation
Acceptable variation within normal clinical practice
Minor deviation that does not need documentation

Correct answer: Protocol deviation that must be documented and reported per study procedures

Consistent departure from protocol-specified administration conditions is a protocol deviation requiring documentation and reporting.

Question 16: What is a needs assessment in CPI Pharmacology & Medication Management practice?

Identifying gaps between current conditions and desired outcomes (Correct answer)
Property appraisal
Benefits survey
Office supply list

Correct answer: Identifying gaps between current conditions and desired outcomes

A needs assessment identifies gaps between current performance and desired outcomes to justify improvements.

Question 17: Under 21 CFR Part 56, which of the following circumstances allows an IRB to conduct expedited review rather than full board review?

Any study amendment that does not change the primary endpoint
Research involving no more than minimal risk and falling within FDA-designated categories of research (Correct answer)
Any Phase I clinical trial involving investigational drugs in adults
All continuation studies where no protocol changes have been made

Correct answer: Research involving no more than minimal risk and falling within FDA-designated categories of research

Expedited review is permitted for minimal-risk research that falls within FDA-published categories or for minor changes to previously approved research.

Question 18: A subject reports taking St. John's Wort herbal supplement daily. Why is this significant during patient assessment in a clinical trial?

St. John's Wort is a potent CYP3A4 inducer that can alter investigational drug metabolism (Correct answer)
It only matters if the subject is also taking anticoagulants
It is not significant because herbal supplements are not medications
Herbal supplements require IRB approval before they can be taken on trial

Correct answer: St. John's Wort is a potent CYP3A4 inducer that can alter investigational drug metabolism

St. John's Wort strongly induces CYP3A4 enzymes, which can significantly reduce plasma levels of many investigational drugs and compromise efficacy or safety assessments.

Question 19: A participant who was lost to follow-up contacts the site reporting a hospitalization that occurred two months ago. The investigator should:

Reopen the participant's case only if the event was fatal
Report it only to the sponsor but not to the IRB since it is retrospective
Ignore the event because it was not reported within the protocol's SAE window
Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria (Correct answer)

Correct answer: Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria

Retrospective SAE reports must still be assessed, documented, and reported if they meet SAE criteria; there is no regulatory exemption for late discovery.

Question 20: Under ICH E6(R2) GCP, the investigator's primary responsibility regarding protocol deviations is to:

Document all deviations and notify the IRB/ethics committee and sponsor as required (Correct answer)
Halt the entire study pending a full regulatory audit
Correct the deviation quietly without documentation to avoid regulatory scrutiny
Obtain post-hoc approval from only the sponsor, not the IRB

Correct answer: Document all deviations and notify the IRB/ethics committee and sponsor as required

ICH E6(R2) requires investigators to document protocol deviations promptly and report them per sponsor and IRB requirements.

Question 21: What are the primary responsibilities of an investigator in clinical research?

To recruit participants
To manage the budget
To ensure ethical conduct and compliance with protocols (Correct answer)
To publish the results

Correct answer: To ensure ethical conduct and compliance with protocols

In clinical research, an investigator's primary responsibility is to protect the rights, safety, and well-being of study participants. This involves strictly adhering to the approved research protocol and all relevant ethical guidelines and regulatory requirements, ensuring the study is conducted with integrity and scientific rigor.

Question 22: An investigator is also a treating physician for a potential study participant. Which conflict of interest concern is MOST relevant to informed consent?

The investigator may disclose proprietary sponsor information during the consent process
The dual role may impair the participant's ability to freely decline or withdraw without fearing impact on their clinical care (Correct answer)
The investigator may underestimate the participant's medical literacy
The IRB will automatically disqualify the investigator from obtaining consent

Correct answer: The dual role may impair the participant's ability to freely decline or withdraw without fearing impact on their clinical care

The therapeutic misconception and fear of jeopardizing ongoing care can compromise voluntariness when the treating physician is also the investigator.

Question 23: During a monitoring visit, a sponsor's clinical research associate (CRA) finds undocumented protocol deviations that may have affected participant safety. What is the MOST appropriate next step?

Correct the records retroactively without informing the IRB
Ignore minor deviations that did not result in harm
Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs) (Correct answer)
Immediately terminate the site without further review

Correct answer: Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs)

Monitoring findings must be documented and addressed through formal CAPA processes to correct deficiencies and prevent recurrence.

Question 24: What is the primary purpose of a Data Safety Monitoring Board (DSMB) in a clinical trial?

To monitor accumulating data and protect participant safety, recommending early stopping if needed (Correct answer)
To audit the sponsor's financial accounts
To ensure all enrolled participants complete follow-up visits
To market the investigational product to physicians

Correct answer: To monitor accumulating data and protect participant safety, recommending early stopping if needed

A DSMB conducts interim analyses of unblinded data to identify safety signals or clear efficacy, with authority to recommend stopping or modifying a trial.

Question 25: A Phase III protocol requires 'overall survival' (OS) as the primary endpoint. A Data Safety Monitoring Board (DSMB) reviews interim data and recommends early trial termination for efficacy. The investigator's role at this point is to:

Continue the trial without informing subjects until the DSMB publishes its findings
Follow the sponsor's instructions based on the DSMB recommendation, including stopping enrollment and notifying subjects (Correct answer)
Override the DSMB recommendation if they disagree with the finding
Immediately unblind all subjects and inform them of their treatment assignment

Correct answer: Follow the sponsor's instructions based on the DSMB recommendation, including stopping enrollment and notifying subjects

When a DSMB recommends early termination for efficacy, the investigator follows sponsor directives, which include stopping enrollment and notifying subjects and the IRB per protocol procedures.

Question 26: Which form is used to report post-market safety problems with FDA-regulated products to the FDA?

FDA Form 483
FDA Form 1572
FDA MedWatch Form 3500 (Correct answer)
IND Annual Report Form

Correct answer: FDA MedWatch Form 3500

MedWatch Form 3500 (voluntary) or 3500A (mandatory for industry) is the FDA's safety reporting form for adverse events with regulated products.

Question 27: An investigator receives new safety information from the sponsor about an increased risk associated with the investigational product. What is the MOST immediate obligation?

Disregard unless FDA issues a formal safety alert
Suspend enrollment until the IRB reviews the information
Wait for a protocol amendment before taking any action
Assess the impact on enrolled subjects and notify the IRB in a timely manner (Correct answer)

Correct answer: Assess the impact on enrolled subjects and notify the IRB in a timely manner

Investigators must promptly assess new safety information and report it to the IRB, as it may require consent form updates or protocol changes to protect subjects.

Question 28: A study drug is a potent inhibitor of P-glycoprotein (P-gp). A participant is concurrently taking digoxin. What is the expected drug-drug interaction?

No change in digoxin levels
Increased digoxin plasma concentrations (Correct answer)
Decreased digoxin plasma concentrations
Accelerated digoxin renal excretion

Correct answer: Increased digoxin plasma concentrations

P-gp normally effluxes digoxin from enterocytes and renal tubular cells; P-gp inhibition increases digoxin absorption and reduces its secretion, raising plasma levels.

Question 29: According to CTCAE v5.0, a subject experiences alanine aminotransferase (ALT) elevation at 4 times the upper limit of normal (ULN) with no symptoms. This represents which grade of adverse event?

Grade 3 (Correct answer)
Grade 4
Grade 1
Grade 2

Correct answer: Grade 3

CTCAE Grade 3 for ALT elevation is defined as >3.0–20x ULN, so a 4x ULN elevation falls within Grade 3.

Question 30: What is 'assent' in the context of pediatric clinical research?

A minor's affirmative agreement to participate in research, supplementing parental permission (Correct answer)
The FDA's approval of a pediatric study protocol
The parent's legally binding consent for their child to participate
An IRB waiver allowing enrollment without full consent

Correct answer: A minor's affirmative agreement to participate in research, supplementing parental permission

Assent is the child's affirmative agreement to participate, required in addition to parental or guardian permission for research involving minors capable of providing meaningful agreement.

Question 31: RECIST 1.1 criteria for tumor response assessment classify a ≥30% decrease in the sum of diameters of target lesions as:

Complete Response (CR)
Stable Disease (SD)
Partial Response (PR) (Correct answer)
Progressive Disease (PD)

Correct answer: Partial Response (PR)

RECIST 1.1 defines Partial Response (PR) as at least a 30% decrease in the sum of diameters of target lesions compared to baseline.

Question 32: A participant with mild cognitive impairment wishes to enroll in a clinical trial. Which approach best satisfies ethical requirements?

Exclude the participant automatically due to impaired cognition
Enroll the participant using only surrogate consent without assessing personal capacity
Assess decision-making capacity individually and involve a legally authorized representative if needed (Correct answer)
Obtain verbal consent only, as written consent may be confusing

Correct answer: Assess decision-making capacity individually and involve a legally authorized representative if needed

Capacity must be assessed individually; participants who retain sufficient capacity should consent themselves, with a LAR involved if capacity is insufficient.

Question 33: In risk management for clinical research, what does 'residual risk' mean?

Risk that has been completely eliminated by safety controls
Risk recorded in the protocol but not yet evaluated
The level of risk that remains after all risk mitigation measures have been implemented (Correct answer)
The risk accepted by the sponsor on behalf of the investigator

Correct answer: The level of risk that remains after all risk mitigation measures have been implemented

Residual risk is the remaining risk after controls are applied; it must be acceptable relative to anticipated benefits for the trial to proceed.

Certified Principal Investigator (CPI®)

The CPI® certification validates the expertise of physicians and advanced practice clinicians serving as principal investigators in clinical trials, covering GCP compliance, ethical conduct, site management, and data integrity across all phases of clinical research.

Questions

40 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds